PREIMPLANTATION GENETIC DIAGNOSIS MARKET ANALYSIS

Preimplantation Genetic Diagnosis Market Size and Trends

Global preimplantation genetic diagnosis market is estimated to be valued at USD 57.1 Mn in 2024 and is expected to reach USD 95.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.6% from 2024 to 2031.

To learn more about this report, Request sample copy

Rising infertile population, increasing public awareness about PGD, growing acceptance of assisted reproductive technologies and rising prevalence of genetic disorders can drive the market growth. However, strict regulations associated with PGD and ethical & legal issues related to embryonic research and clinical diagnosis can hamper the market growth. Growing pharmaceutical and biotech industry and ongoing research and development activities to introduce advanced preimplantation diagnosis techniques can offer new growth opportunities for the market growth in the near future.

Rising Prevalence of Genetic Disorders

With advancements in genetic science, people’s understanding of genetic disorders and diseases has increased tremendously over the past few decades.  Researchers have identified genetic mutations and errors that can lead to a host of medical conditions affecting individuals from birth throughout their lives. Some common genetic disorders include cystic fibrosis, Down syndrome, fragile X syndrome, Huntington's disease, muscular dystrophy, and others. The prevalence of these single-gene and chromosomal disorders has been rising globally. As per some estimates, over 7,000 rare disorders have been characterized so far and around 350 new disorders are identified each year. This rising disease burden due to genetic factors can boost utilization of preimplantation genetic diagnosis. With PGD, genetic disorders can be detected in embryos even before pregnancy, allowing parents to transfer only healthy embryos. This helps couples who are carriers of genetic mutations to have a healthy baby and avoid passing on diseases to their offspring. It is bringing hope to families with a history of genetic conditions in alleviating anxiety and improving outcomes. The technique is highly valued as it prevents suffering for the potential child and provides answers to parents who would otherwise take the risk of conceiving naturally. For instance, in April 2023, The Prelude Network and The HelpCureHD Foundation initiated the More Than Infertility campaign. This campaign aims to educate and raise awareness about IVF with preimplantation genetic testing (PGT) as a means to reduce genetic disorders like Huntington's disease in newborns.

To learn more about this report, Request sample copy

Rising Emphasis on Family Planning

In modern times, there is a lot more emphasis on carefully planning one's family and having children through a conscious decision rather than leaving everything to chance. People are delaying parenthood, having fewer children on average and are highly invested in each child's wellbeing and success. Moreover, societal pressures of earning higher degrees, establishing careers and achieving financial stability before starting a family have also increased significantly. This shifts the outlook towards family intensely. Preimplantation genetic diagnosis fits neatly as it allows testing of embryos for genetic defects before pregnancy. It empowers couples to have more control over their fecundity and family size. With the technique, people can feel confident about anticipating or avoiding hereditary health problems in offspring. The option to select healthy embryos alleviates uncertainties involved in natural conception. It streamlines the family planning approach and aligns it with modern preferences around informed choice and optimization.